Deep Brain Stimulation and Obsessive-compulsive Disorder

Obsessive-Compulsive Disorder Clinical Trial

— STOC2  

Official title:

Treatment of Severe and Resistant Obsessive-compulsive Disorder by High-frequency Stimulation of the Ventral Striatum and the Subthalamic Nucleus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01329133
• Other study ID #: CHUBX 2010/43
• Status: Completed
• Phase: Phase 3
• Start date: April 4, 2011
• Est. completion date: April 2019

Study information

• Verified date: February 2020
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obsessive-compulsive disorder (OCD) is a relatively common psychiatric condition, which is classically treated by antidepressant medications in combination with psychotherapies. However, both these conventional therapeutic approaches fail to sufficiently improve obsessive-compulsive symptoms in 20-30% of cases. From these considerations, deep brain stimulation (DBS), as a reversible and adjustable surgical procedure, has recently been introduced in the field of resistant OCD. DBS currently uses electrodes with four contacts on each lead, which are bilaterally implanted into the chosen brain structure. DBS consists of the delivery of a high-frequency current through the quadripolar electrodes connected to a battery powered pulse-generating device. Several clinical investigations have shown that DBS, primarily targeting either the ventral striatum (VS) or the subthalamic nucleus (STN), as brain sites of interest because of their particular involvement in the production of OCD symptoms, is able to produce an approximately 40% or greater reduction in clinical symptom intensity in severely chronic and incapacitating forms of OCD. These promising findings lead to propose a comparison of the efficacy, safety and tolerability of DBS choosing either the VS or STN as brain target by conducting a large controlled trial and including a medico-economic analysis for assessing the classical cost/efficacy ratio. In this way, the present study is expected to promote and highlight the importance of DBS, as an effective, safe, well-tolerated and cost-relevant surgical approach for the management of resistant OCD.

Description:

Obsessive-compulsive disorder (OCD) is a relatively common psychiatric condition with an estimated lifetime prevalence of 2-3 % of the general population. It is generally characterized by a chronic course leading to a profound impairment in psychosocial functioning and to a marked deterioration in quality of life. Today, the well-established efficacy of antidepressants, acting preferentially by blocking serotonin reuptake, in addition to psychological treatments, have considerably changed the poor prognosis of the illness. However, both conventional therapeutic approaches failed to substantially alleviate obsessive-compulsive symptoms in 20-30% of cases. Deep brain stimulation, as a reversible and adjustable surgical procedure, has recently been introduced in the field of OCD, primarily targeting either the ventral striatum (VS) or the subthalamic nucleus (STN) and leading to an approximately 40% or greater reduction in clinical symptom intensity from baseline levels in severely chronic and resistant forms of OCD. These promising findings lead to propose a comparison of the efficacy, safety and tolerability of DBS choosing either the VS or STN as brain target by conducting a multicenter, parallel-group, randomized, single-blind trial over a 13-month follow-up period. For this purpose, a total population of 28 OCD patients who meet the currently used operational criteria for defining therapeutic resistance will be recruited. The surgical procedure will consist in the implantation of stimulation electrodes with four contacts on each lead, which are stereotactically and bilaterally implanted into the targeted brain structure under local anesthesia. Per-operative, single-unit electrophysiological recordings of the neuronal activity will be performed using five parallel microelectrodes and serving as guide for the implantation of both definitive electrodes. They will be connected to a battery powered pulse-generating device five days later under general anesthesia. Thereafter, psychiatric assessments including both the Y-BOCS ("Yale-Brow Obsessive-compulsive scale") and PI ("Padua Inventory") for measuring OCD symptom severity, the BAS ("Brief Anxiety Scale"), MADRS ("Montgomery and Asberg Depression rating Scale") and HAD ("Hospital Anxiety and Depression Scale") for determining anxiety and/or depressive symptom intensity, and the CGI ("Clinical Global Impression") rating scales for evaluating global symptom severity and treatment response will be performed every 3 months beyond the one-month postoperative free-stimulation period. This will be coupled with a large battery of neuropsychological tests exploring all executive functions in combination with precise medical records of side effects for appreciating safety/tolerability of DBS. A cost-effectiveness analysis, as a formal method of comparing DBS and classical therapeutic strategies with regard to their respective resource utilization (costs) and outcomes (effectiveness) will also be carried out. Therefore, the present study may contribute to highlight the special interest of DBS, as an effective, safe, well-tolerated and cost-relevant surgical approach for the management of resistant OCD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age comprised between 18 and 60 years

• History of OCD for at least 5 years according to the DSM-IV-TR criteria and characterized by a "good insight", as determined by the BABS ("Brown Assessment of Beliefs Scale")

• Severe form of OCD, as evidenced by:

• a score = 25 on the Y-BOCS

• a score > 4 on the CGI scale

• a score =< 40 on the GAF ("global assessment of functioning)

• Lack of therapeutic effects of at least 3 antidepressants selectively blocking serotonin reuptake (SSRI) at least 12 consecutive weeks at the maximal tolerated dose (up to 80 mg/day for fluoxetine, 300 mg/day for fluvoxamine, 200 mg/day for sertraline, 60 mg/day for paroxetine, 60mg/day for citalopram and 250 mg/day for clomipramine) prescribed alone and in combination for at least 1 month with: 1) risperidone or olanzapine or aripiprazole or quetiapine, 2) clomipramine

• Lack of therapeutic effects of behavioral therapy with two different therapists using conventional techniques primarily based on exposure with prevention of ritualized response

• Understand and accept the design and constraints of the present study

• Be a beneficiary or member of health insurance plan

• Provide written consent to the study after receiving clear information

Exclusion Criteria:

• Patient with cognitive impairment with a Mattis scale score = 130

• Patient with other DSM-IV-TR axis I diagnoses (schizophrenia, bipolar, substance abuse or substance dependence), except for generalized anxiety disorder, social phobia or nicotine dependence

• Patient with high suicide risk, as indicated by a score = 2 on the MADRS (item 10)

• Patient with personality disorder corresponding to the clusters A and B, as assessed with the SIDP-IV ("Structured Interview for DSM-IV Personality")

• Patient with contraindication for MRI scanning, abnormal brain MRI or serious intercurrent disease

• Patient with contraindication for surgery or anesthesia

• Patient currently treated with anticoagulant or antiplatelet drug

• Be a woman of childbearing age without effective contraception

• Be hospitalized under constraint

• Be under guardianship procedures

• Prohibition on participation in other research, apart from any other non-interventional research

Related Conditions & MeSH terms

• Disease
• Obsessive-Compulsive Disorder

Intervention

Procedure:
• Deep Brain Stimulation (DBS)
In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.

Locations

Country	Name	City	State
France	Bordeaux University Hospital	Bordeaux
France	Clermont-Ferrand University Hospital	Clermont-Ferrand
France	Henri Mondor Hospital	Créteil
France	Grenoble University Hospital	Grenoble
France	Lille University Hospital	Lille
France	Lyon University Hospital	Lyon
France	Marseille University Hospital	Marseille
France	Nice University Hospital	Nice
France	Pitié-Salpêtrière Hospital	Paris
France	Sainte-Anne Hospital	Paris
France	Poitiers University Hospital	Poitiers
France	Rennes University Hospital	Rennes
France	Strasbourg University Hospital	Strasbourg
France	Toulouse University Hospital	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

References & Publications (2)

Aouizerate B, Cuny E, Bardinet E, Yelnik J, Martin-Guehl C, Rotge JY, Rougier A, Bioulac B, Tignol J, Mallet L, Burbaud P, Guehl D. Distinct striatal targets in treating obsessive-compulsive disorder and major depression. J Neurosurg. 2009 Oct;111(4):775-9. doi: 10.3171/2009.2.JNS0881. — View Citation

Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13;359(20):2121-34. doi: 10.1056/NEJMoa0708514. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Combination of three criteria (composite criterion), as follows: a. Y-BOCS score = 16 / and b. Technical feasibility (each leads in the target) / and c. Safety, as assessed by any serial adverse event		Month 13 : one year after stimulation
Secondary	Remission as defined by a Y-BOCS score = 16 at M13		Month 13 : one year after stimulation
Secondary	Number of electrode contacts correctly located within the chosen brain target (0, 1 or 2)		End of surgical procedure (day 1)
Secondary	Monitoring of psychological and somatic complaints made spontaneously by the patient over the course of the present trial, in combination to the semi-structured interview for collecting side effects		Every 3 months from Month 1 to Month 13
Secondary	Scores on neuropsychological tests exploring all executive functions		Every 3 months from Month 1 to Month 13
Secondary	Percentage change in the total Y-BOCS score from M1 to M13		Every 3 months from Month 1 to Month 13
Secondary	Therapeutic response, as indicated by a 35% decrease or more in the Y-BOCS score and a score of 1 or 2 (very much or much improved) on the CGI improvement scale from M1 to M13		Every 3 months from Month 1 to Month 13
Secondary	Percentage change in the Y-BOCS obsessive and compulsive subscores from M1 to M13		Every 3 months from Month 1 to Month 13
Secondary	Percentage change in the overall Padua Inventory score, MADRS score, BAS score from M1 to M13		Every 3 months from Month 1 to Month 13
Secondary	Percentage change in the total and depression and anxiety subscale scores on the HAD scale from M1 and M13		Every 3 months from Month 1 to Month 13
Secondary	Ratings of functional disability and quality of life		Every 3 months from Month 1 to Month 13
Secondary	Correlations between efficacy and anatomical positioning of both stimulation electrodes within the chosen brain target		Every 3 months from Month 1 to Month 13
Secondary	cost comparison of therapeutic strategies	cost comparison of thérapeutic strategies : classical versus surgical	M-13 and M13 (one year after stimultaion)
Secondary	Cost / effectiveness ration	Cost / effectiveness ratio : cost difference between therapeutic strategies and success rate of DBS	M-13/ M13 (one year after stimulation)
Secondary	Cost-utility rati	Cost-utility ratio based on SF-36 scores.	every 3 months from month 1 to month 13